Relation between dexamethasone (DEX) usage, preventive trimetprim/sulfametoxazole (ST), and pneumocystis pneumonia (PCP) for patients with breast cancer receiving dose-dense AC followed by dose-dense paclitaxel (ddAC-ddP): Preplanned analysis of WJOG9016B.

Koji Matsumoto,Meiko Nishimura,Yukinori Ozaki,Manabu Futamura,Toshikio Miyaki,Junji Tsurutani,Shigeru Imoto,Mihoko Doi,Shinya Tokunaga,Kenjiro Aogi,Kenichi Yoshimura,Hideaki Okada,Yasuaki Sagara,Motoi Baba,Shigenori E. Nagai,Toshimi Takano

Relation between dexamethasone (DEX) usage, preventive trimetprim/sulfametoxazole (ST), and pneumocystis pneumonia (PCP) for patients with breast cancer receiving dose-dense AC followed by dose-dense paclitaxel (ddAC-ddP): Preplanned analysis of WJOG9016B.

2019

Koji Matsumoto
Meiko Nishimura
Yukinori Ozaki
Manabu Futamura
Toshikio Miyaki
Junji Tsurutani
Shigeru Imoto
Mihoko Doi
Shinya Tokunaga
Kenjiro Aogi
Kenichi Yoshimura
Hideaki Okada
Yasuaki Sagara
Motoi Baba
Shigenori E. Nagai
Toshimi Takano

e12022Background: PCP is rare complication of ddAC-ddP. DEX is plausible risk factor for PCP. Dose and duration of DEX against CINV is changing over time as other anti-emetic drugs (5HT3 RA, NK1 RA...

Keywords:

Dexamethasone
Risk factor
Pneumocystis pneumonia
Oncology
Breast cancer
Complication
Paclitaxel
Internal medicine
Pathology
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations